Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EXAS

EXAS - Exact Sciences Corp Stock Price, Fair Value and News

$102.25-0.09 (-0.09%)
Market Closed

33/100

EXAS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

33/100

EXAS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$81.81

Target 3M

$95.1

Target 6M

$88.56

EXAS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EXAS Price Action

Last 7 days

-0.2%

Last 30 days

0.3%

Last 90 days

61.7%

Trailing 12 Months

84.5%

EXAS RSI Chart

EXAS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EXAS Valuation

Market Cap

19.4B

Price/Earnings (Trailing)

-19.64

Price/Sales (Trailing)

6.29

EV/EBITDA

-22.34

Price/Free Cashflow

78.41

EXAS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$81.81

Target 3M

$95.1

Target 6M

$88.56

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

3.1B

Rev. Growth (Yr)

20.05%

Rev. Growth (Qtr)

4.89%

EXAS Earnings

Earnings (TTM)

-986.6M

Earnings Growth (Yr)

48.76%

Earnings Growth (Qtr)

-1.6K%

EXAS Profitability

Operating Margin

69.42%

EBT Margin

-32.28%

Return on Equity

-39.44%

Return on Assets

-16.72%

Free Cashflow Yield

1.28%

EXAS Investor Care

Shares Dilution (1Y)

2.37%

Diluted EPS (TTM)

-5.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.8B2.9B3.1B0
20242.5B2.6B2.7B2.8B
20232.2B2.3B2.4B2.5B
20221.9B1.9B2.0B2.1B
20211.5B1.7B1.8B1.8B
20201.1B1.1B1.3B1.5B
2019526.2M623.2M723.7M876.3M
2018307.9M353.2M398.9M454.5M
2017132.9M169.4M213.8M266.0M
201650.0M63.1M78.6M99.4M
20155.8M13.9M26.5M39.4M
20143.4M2.4M1.3M1.8M
20134.1M4.1M4.1M4.1M
20124.2M4.2M4.2M4.1M
20115.1M4.8M4.5M4.2M
20100005.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Exact Sciences Corp

EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
 CEO
 WEBSITEexactsciences.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES6300

Exact Sciences Corp Frequently Asked Questions

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Exact Sciences Corp is 19.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EXAS's fair value in chart for subscribers.

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

As of Wed Jan 28 2026, EXAS's PE ratio (Price to Earnings) is -19.64 and Price to Sales (PS) ratio is 6.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Exact Sciences Corp has provided 0.316 (multiply by 100 for percentage) rate of return.